Kimberly-Clark Closes the Kenvue Deal; Now It Has to Earn It

Kimberly-Clark completed its acquisition of Kenvue on Monday, turning a year-old agreement into one combined consumer health and personal care company.

Kenvue shareholders receive $3.50 in cash and 0.14625 Kimberly-Clark shares for each Kenvue share they held. Kenvue stock ceased trading at Monday's market open on the New York Stock Exchange.

Chief Executive Mike Hsu called the close "a defining moment in Kimberly-Clark's 154-year history." The combined company serves consumers in more than 175 countries, Kimberly-Clark said.

The synergy promise has a price tag

Kimberly-Clark reaffirmed its target of about $2.1 billion in annual run-rate synergies. Run-rate synergies are the yearly savings and extra profit expected once integration is complete. They are a company target, not a reported result.

The company expects about $1.9 billion of cost synergies within three years of the close. It expects about $500 million more in profit from revenue synergies within four years. About $300 million is set to be reinvested, which is how the pieces net to $2.1 billion.

Against that promise sits the integration bill, set out in the company's Form 8-K filing on Monday. A Form 8-K is the standard regulatory report for major corporate events. The filing describes a Kenvue Integration Program running through the end of 2029.

The program is expected to bring about $3.1 billion in pretax charges over that period. About $2.5 billion of the charges are cash, and about $600 million are non-cash. The company also expects about $1.4 billion in capital spending tied to the program.

Together, the charges and the capital spending come to about $4.5 billion. That total is a calculation from the company's figures, not a company total. It is the amount the combined business must spend before the full synergy target is reached.

Supply-chain network optimization is the largest cash cost, at about $800 million. Enterprise resource planning and technology integration add about $600 million. That work means merging the two companies' core planning and business systems. Workforce optimization and advisory services are each about $400 million.

A bigger company, in four pieces

The combined company counts 10 billion-dollar brands. They are Huggies, Listerine, Cottonelle, Neutrogena, Depend, Tylenol, Kleenex, Johnson's Baby, Kotex and Scott. Kenvue is the consumer-health business behind brands such as Tylenol, Listerine and Neutrogena.

Kimberly-Clark will now operate through four business segments. The sales figures are management estimates for combined fiscal 2025 sales. They are not the formal pro forma figures securities rules prescribe, and the company labels them as estimates.

North America is the largest segment, at about $18.0 billion in those estimated sales. Europe, the Middle East and Africa is next, at about $5.0 billion. Asia Pacific Focus Markets and Enterprise Markets are each about $4.3 billion.

The stock payment enlarged the buyer itself. Kimberly-Clark delivered, or has an obligation to deliver, about 281 million new shares to former Kenvue holders. The exact count in the filing is 281,060,840 shares.

Three Kenvue directors joined the Kimberly-Clark board at the close. They are Richard E. Allison Jr., Larry J. Merlo and Kirk L. Perry. The board now has 13 members. Mae C. Jemison, Christa S. Quarles and Jaime A. Ramirez stepped down to create the vacancies, the filing says.

How the deal got here

The merger agreement was signed on November 2, 2025, and announced the next day. It valued Kenvue at an enterprise value of about $48.7 billion. Enterprise value is a deal value that includes assumed debt.

Shareholders of both companies approved the deal on January 29, 2026. The Hart-Scott-Rodino antitrust waiting period, the federal review window, expired on February 4, 2026. Foreign approvals and other closing conditions then took most of the year to clear.

The original plan expected about 280 million shares and about $6.7 billion in cash. The final share count landed close to plan. To help fund the cash, Kimberly-Clark priced $4.9 billion of senior notes in October 2026. Senior notes are a standard form of corporate borrowing.

Investors are waiting for proof

The first market verdict was quiet. In an intraday snapshot at about 12:35 p.m. Eastern on Monday, Kimberly-Clark shares traded at $108.76. That was up 0.76% from the previous close of $107.94.

The snapshot showed an open of $109.24, a high of $111.38 and a low of $107.55. Those are intraday figures at that moment, not closing prices. A move under 1% fits a deal the market had a full year to price in.

The debate now changes. It is no longer whether the deal happens, but whether the promised savings arrive on schedule. It is also whether they arrive without the integration costs growing past the filed estimates.

What remains unknown

What remains unknown starts with delivery. The synergy figures are targets with three- and four-year timetables. The release does not give a year-by-year schedule for how much arrives, and when.

Also unknown is the final integration cost. The filing warns that its charge estimates rest on assumptions. It also says other charges, not currently contemplated, may arise as the program runs.

The combined sales figures are management estimates, not audited results for the new segments. How the four segments actually perform together will only show in coming quarterly reports. Their first reported numbers will replace estimates with evidence.

What to watch next

What to watch begins with the first combined quarterly results. They will show the new segment structure in reported numbers, rather than estimates. They should also show the first integration charges booked against the program.

Watch the pace of those charges each quarter against the $3.1 billion program total. Front-loaded costs with visible savings tell one story. Costs that drift upward, without savings to match, tell another.

Watch the synergy language, too. Any move away from the $2.1 billion run-rate target, or a slower timetable, changes the deal's math. About 281 million new shares and the October borrowing both have to be earned back through combined earnings.